Cagrilintide vs Tesofensine

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is appetite control and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — Cagrilintide rates 5/5 for appetite control and Tesofensine rates 5/5. Outside that overlap only Cagrilintide goes further, carrying weight for metabolic health; Tesofensine's declared goals stop at the overlap.

Tesofensine sits one step firmer: approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. Cagrilintide has controlled human trials behind it, without an approval — investigational; standalone long-term data does not exist yet. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

Cagrilintide is a subcutaneous injection; Tesofensine is taken by mouth. That is the difference most people actually feel: Cagrilintide means reconstituting a vial and injecting; Tesofensine does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Half-lives are close — 7.5 days for Cagrilintide, 9.2 days for Tesofensine — yet the schedules are not: once a week versus once daily. Similar clearance and different dosing means the difference comes from protocol convention, not from how fast either one leaves you.

One of these has an end date and the other does not: Cagrilintide runs no fixed cycle, Tesofensine runs 24 weeks. An open-ended compound is a standing commitment, not a course you finish. Cagrilintide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.